Product image of Gonasi Hp (Chorionic Gonadotrophin) supplied by GNH India

Gonasi Hp

Active Ingredient:
Chorionic Gonadotrophin
Origin:
EU

Gonasi Hp (Chorionic Gonadotrophin)

Gonasi Hp is a pharmaceutical product that contains the active ingredient chorionic gonadotrophin. It is supplied in an injectable form for intramuscular or subcutaneous administration. The specific strength and dosage form are not disclosed, and the product is marketed in the European Union. Gonasi Hp belongs to the gonadotropin drug class and is used in clinical settings related to reproductive health.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Gonasi Hp is employed in medical practice where stimulation of the gonadal axis is required. Its clinical applications include:

  • Supporting follicular development in assisted reproductive technology procedures.
  • Inducing ovulation in women with certain ovulatory disorders.
  • Promoting luteal phase support after ovulation induction.
  • Assisting in the treatment of specific cases of male hypogonadism.
  • Facilitating the development of secondary sexual characteristics in selected endocrine conditions.

Side Effects

Side effects of chorionic gonadotrophin may vary in frequency and severity.

Common

  • Injection site pain or erythema.
  • Mild headache.
  • Nausea or mild gastrointestinal discomfort.
  • Transient abdominal bloating.
  • Mild fatigue.

Serious

  • Ovarian hyperstimulation syndrome (OHSS).
  • Allergic reactions such as rash, itching, or anaphylaxis.
  • Thromboembolic events.
  • Severe abdominal pain indicating ovarian cyst rupture.
  • Persistent swelling or fluid accumulation (ascites).

Precautions & Warnings

When considering Gonasi Hp, healthcare providers should evaluate several safety factors. Important precautions include:

  • Assessing the patient's history of ovarian hyperstimulation or thromboembolic disease.
  • Monitoring hormone levels and ovarian response during treatment.
  • Using caution in patients with known hypersensitivity to gonadotropins.
  • Evaluating cardiovascular risk, especially in patients with hypertension or clotting disorders.
  • Adjusting therapy for individuals with renal or hepatic impairment.
  • Ensuring appropriate contraception for women of reproductive age not undergoing fertility treatment.

Avoid Interactions

Chorionic gonadotrophin may interact with other medications or substances. Interaction considerations are:

Avoid

  • Concurrent use of drugs that increase the risk of thrombosis (e.g., estrogen‑containing contraceptives).
  • Medications that may exacerbate ovarian hyperstimulation, such as high‑dose gonadotropin analogues.

Use with caution

  • Anticoagulants, due to potential changes in clotting risk.
  • Steroids that affect fluid balance.
  • Thyroid hormone therapy, as thyroid status can influence reproductive response.
  • Medications that alter hormone metabolism (e.g., certain antiepileptics).

Frequently Asked Questions

Gonasi Hp contains chorionic gonadotrophin as its active pharmaceutical ingredient.

The product is supplied for intramuscular or subcutaneous injection.

Yes, Gonasi Hp is marketed and available in the EU.

It is used to support follicular development, induce ovulation, provide luteal phase support, and treat certain cases of male hypogonadism.

Common reactions include injection site pain, mild headache, nausea, abdominal bloating, and fatigue.

Serious events can include ovarian hyperstimulation syndrome, allergic reactions, thromboembolic events, ovarian cyst rupture, and significant fluid accumulation.

Patients with a history of thrombosis should be evaluated carefully, and the medication may be avoided or used only under strict medical supervision.

Concurrent use with estrogen‑containing contraceptives is generally avoided because it may increase the risk of thrombosis.

Regular assessment of hormone levels, ultrasound monitoring of ovarian response, and observation for signs of hyperstimulation are recommended.

Dose adjustments and close monitoring are advised for patients with significant hepatic or renal impairment.

Yes, although rare, allergic reactions such as rash, itching, or anaphylaxis can occur and require immediate medical attention.

Severe abdominal pain may indicate ovarian cyst rupture or OHSS; the patient should seek urgent medical evaluation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Chorionic Gonadotrophin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT